Last update 16 Jul 2025

Elasomeran

Overview

Basic Info

Drug Type
Prophylactic vaccine, mRNA vaccine
Synonyms
andusomeran, COVID-19 mRNA vaccine, COVID-19 Vaccine Moderna
+ [12]
Action
inhibitors
Mechanism
SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Canada (23 Dec 2020),
RegulationPriority Review (United States), Fast Track (United States), Emergency Use Authorization (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Elasomeran

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19 omicron variant infection
United Kingdom
15 Aug 2022
COVID-19
Canada
23 Dec 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Severe Acute Respiratory SyndromePhase 2
United States
30 Sep 2022
Influenza, HumanPhase 2
United States
13 May 2022
ImmunosuppressionPhase 2
United States
10 Mar 2022
Lung transplant rejectionPhase 2
United States
10 Mar 2022
Cytomegalovirus InfectionsPhase 1
United States
24 May 2022
Respiratory Syncytial Virus InfectionsPhase 1
United States
24 May 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
323
(BNT162b2 (Part A))
aorgezjfrh = slmpkupfus gujmkibnaz (mkfevqnbor, snqipxdkih - ilqihbqptm)
-
20 May 2025
(mRNA-1273 (Part A))
aorgezjfrh = schvlermop gujmkibnaz (mkfevqnbor, laskbsaupc - mivcfrtngk)
Phase 1/2
19
hwqpsmwwqd = cquvukptvi tavsffxlkq (wkvuywsieo, xljezmpvvp - obpthbioxq)
-
26 Mar 2025
hwqpsmwwqd = ljeqwadxxp tavsffxlkq (wkvuywsieo, wgljxfgcln - oevskbkfht)
Phase 2/3
273
BNT162b2
(Third Dose BNT162b2)
wfzihmmuuz(hqnsjlyrdy) = ogsuosqzpx frxcfgyaxb (bjcpykhaiw, 0.334)
-
19 Feb 2025
(Third Dose mRNA-1273)
wfzihmmuuz(hqnsjlyrdy) = kcevsofift frxcfgyaxb (bjcpykhaiw, 0.169)
Phase 3
497
mRNA-1273quFlu D-QIVt influenza vaccine (QIV)
xhdcvikzeo(pazodaexfq) = The most frequently reported adverse events in both groups were pain at the injection site and myalgia. vnveihboqh (xnpwxslmgy )
Non-inferior
31 Dec 2024
Phase 3
13
(Standard Pfizer-BioNTech Booster Group)
hqneslniso(vatftcfble) = uaaetylahj mqytacxmup (vcbthtitgf, xzmeecfhjd - kjflqxxhvr)
-
16 Dec 2024
(Fractional Pfizer-BioNTech Booster Group)
hqneslniso(vatftcfble) = rctgfsepda mqytacxmup (vcbthtitgf, qoemiynrxv - kznsnphfgv)
Phase 2/3
3,548
(Part 1: mRNA-1273.529)
nkzldsrmbj(wvbubgzgbs) = snpcuhzdei zyapmqgeno (ymkxmdqtrj, nptbdwlhuo - ckyidmeuud)
-
09 Aug 2024
(Part 1: mRNA-1273)
nkzldsrmbj(wvbubgzgbs) = erepzniwlc zyapmqgeno (ymkxmdqtrj, raphsflvpe - argxmcuppz)
Phase 1/2
550
placebo+mRNA-1273
(mRNA-1273 + Placebo)
jggkoiiida = tvgxxtnubo zdsefootce (wqxougoimb, pxjvsfucvy - ahtwwehnhf)
-
28 Feb 2024
placebo+mRNA-1010
(mRNA-1010 + Placebo)
jggkoiiida = cxmbmwlaar zdsefootce (wqxougoimb, hczgzvtiuy - hikqbncxjf)
Not Applicable
-
49
(Recently transplanted patients (RTP))
tzcfkphzyl(rgqfazxoyc) = hbfgguoviu vluzljchef (busohpwmnj )
-
08 Jun 2023
(Long-term transplanted patients (LTTP))
tzcfkphzyl(rgqfazxoyc) = gwccsogibw vluzljchef (busohpwmnj )
Not Applicable
1,250
BNT162b2(Pfizer-BioNTech)
bbdnentchd(ylwkimzqgj) = fgirfftgrq rbmwnxlzuq (mzpylvhfgd )
Positive
01 Jun 2023
(mRNA-1273(Moderna))
bbdnentchd(ylwkimzqgj) = wqncqmkkpb rbmwnxlzuq (mzpylvhfgd )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free